GMAB Share Price Performance
DKK 0
-1357.50 (-100.00%)
Price DKK 0
Fair ValueDKK 2,392.08
Share Pricen/a
Analysis Article • Aug 09
Genmab A/S Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 159 Fair Values set on narratives written by author
GMAB Community Narratives
AN
Fair Value
·Fair Value DKK 2.39k 16.7% undervalued intrinsic discount
GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain
2users have liked this narrative
1users have commented on this narrative
63users have followed this narrative
AN
Fair Value
·Fair Value DKK 3k 33.6% undervalued intrinsic discount
Precision Medicine And An Aging Population Will Widen Biologics Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value DKK 1.63k 21.9% overvalued intrinsic discount
Escalating Regulatory Scrutiny And Patent Risks Will Constrain Margins
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Escalating Regulatory Scrutiny And Patent Risks Will Constrain Margins
Genmab’s growth story leans heavily on a small set of cancer medicines, and tougher pricing rules, stricter regulators, and looming patent challenges could squeeze what it earns from them. See why that puts so much weight on the next wave of drug launches—and what could still keep the business growing.Read more
AN
DKK 1.63k
21.9% overvalued intrinsic discount
Fair Value
Revenue
11.36% p.a.
Profit Margin
20.53%
Future PE
15.44x
Price in 2029
DKK 1.93k
GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain
Genmab is moving beyond being a royalty story by pushing more of its own cancer medicines into new markets, with multiple late-stage programs and recent launches that could reshape its growth path. The big question is whether it can navigate pricing pressure, tough regulators, and heavy reliance on key partners while it scales up.Read more
AN
DKK 2.39k
16.7% undervalued intrinsic discount
Fair Value
Revenue
16.79% p.a.
Profit Margin
26.45%
Future PE
16.07x
Price in 2029
DKK 2.84k
Precision Medicine And An Aging Population Will Widen Biologics Markets
Genmab could surprise investors if its newer cancer medicines win approvals faster and work for more patients than expected, expanding how many people can use them. But the story also hinges on a small set of treatments and key partners, so policy changes, trial setbacks, or new competing therapies could quickly change the outlook.Read more
AN
DKK 3k
33.6% undervalued intrinsic discount
Fair Value
Revenue
23.03% p.a.
Profit Margin
31.3%
Future PE
14.55x
Price in 2029
DKK 3.57k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
GMAB: 2026 Oncology Readouts Will Expose Darzalex Patent Cliff Risk
Fair Value: DKK 1.63k 21.9% overvalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GMAB: Epkinly Franchise Progress Will Drive 2026 Catalyst-Rich Bullish Outlook
Fair Value: DKK 2.39k 16.7% undervalued intrinsic discount
63 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
GMAB: Upcoming Oncology Readouts Will Test Commercial Model And Earnings Resilience
Fair Value: DKK 3k 33.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Genmab A/S Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 05, 2026
- 13.20
- 93.03%
- 19.08%
- 86.2%
About GMAB
- Founded
- 1998
- Employees
- 3088
- CEO
- WebsiteView website
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
